|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||191.298 g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype. One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co. (Now Pfizer)
- Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Research. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888.
- Chen G, Portman R, Wickel A (November 1951). "Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent". The Journal of Pharmacology and Experimental Therapeutics. 103 (3): 330–6. PMID 14898449.